$43.38
0[0.00%]
At close: Apr 24
$43.38
0[0.00%]
PreMarket: 4:20PM EDT
SpringWorks Therapeutics
(NASDAQ:SWTX)SpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, Predictions
SpringWorks Therapeutics Inc has a consensus price target of $63.17, established from looking at the 31 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, HC Wainwright & Co., and Barclays on March 6, 2024, March 6, 2024, and February 29, 2024. With an average price target of $70.67 between JP Morgan, HC Wainwright & Co., and Barclays, there's an implied 62.90% upside for SpringWorks Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Barclays
Wedbush
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for SpringWorks Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 72.89% | JP Morgan | Anupam Rama | $73 → $74 | Maintains | Overweight | Get Alert |
| 03/06/2024 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 70.59% | HC Wainwright & Co. | Robert Burns | $73 → $74 | Maintains | Buy | Get Alert |
| 02/29/2024 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 45.23% | Barclays | Peter Lawson | $47 → $63 | Maintains | Overweight | Get Alert |
| 02/26/2024 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 61.36% | Wedbush | David Nierengarten | $60 → $70 | Maintains | Outperform | Get Alert |
| 01/25/2024 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 8.34% | Barclays | Peter Lawson | $41 → $47 | Maintains | Overweight | Get Alert |
| 11/29/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 19.87% | Goldman Sachs | Corinne Jenkins | $47 → $52 | Maintains | Buy | Get Alert |
| 11/29/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 68.28% | HC Wainwright & Co. | Robert Burns | $64 → $73 | Maintains | Buy | Get Alert |
| 11/28/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 47.53% | HC Wainwright & Co. | Robert Burns | $52 → $64 | Maintains | Buy | Get Alert |
| 11/20/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 19.87% | HC Wainwright & Co. | Robert Burns | $58 → $52 | Maintains | Buy | Get Alert |
| 11/09/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 33.7% | HC Wainwright & Co. | Robert Burns | $66 → $58 | Maintains | Buy | Get Alert |
| 08/24/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 52.14% | HC Wainwright & Co. | Robert Burns | → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 52.14% | HC Wainwright & Co. | Robert Burns | $105 → $66 | Maintains | Buy | Get Alert |
| 07/20/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 12.96% | Goldman Sachs | Corinne Jenkins | $43 → $49 | Maintains | Buy | Get Alert |
| 06/06/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 142.05% | HC Wainwright & Co. | Robert Burns | → $105 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 142.05% | HC Wainwright & Co. | Robert Burns | → $105 | Reiterates | → Buy | Get Alert |
| 04/28/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | -5.49% | Barclays | Peter Lawson | $55 → $41 | Maintains | Overweight | Get Alert |
| 04/20/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 142.05% | HC Wainwright & Co. | Robert Burns | → $105 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 31.4% | JP Morgan | Anupam Rama | $53 → $57 | Maintains | Overweight | Get Alert |
| 03/07/2023 | SWTX | Buy Now | SpringWorks Therapeutics | $43.38 | 142.05% | HC Wainwright & Co. | Robert Burns | $99 → $105 | Maintains | Buy | Get Alert |
FAQ
What is the target price for SpringWorks Therapeutics (SWTX)?
The latest price target for SpringWorks Therapeutics (NASDAQ: SWTX) was reported by JP Morgan on March 6, 2024. The analyst firm set a price target for $75.00 expecting SWTX to rise to within 12 months (a possible 72.89% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for SpringWorks Therapeutics (SWTX)?
The latest analyst rating for SpringWorks Therapeutics (NASDAQ: SWTX) was provided by JP Morgan, and SpringWorks Therapeutics maintained their overweight rating.
When was the last upgrade for SpringWorks Therapeutics (SWTX)?
There is no last upgrade for SpringWorks Therapeutics.
When was the last downgrade for SpringWorks Therapeutics (SWTX)?
There is no last downgrade for SpringWorks Therapeutics.
When is the next analyst rating going to be posted or updated for SpringWorks Therapeutics (SWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating SpringWorks Therapeutics (SWTX) correct?
While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a maintained with a price target of $74.00 to $75.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $43.38, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.